Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

THE OPTIMAL TIMING OF PRIMAQUINE TO PREVENT MALARIA TRANSMISSION AFTER ARTEMISININ-COMBINATION THERAPY

NCT01906788 is registered in ClinicalTrials.gov with Kilimanjaro Clinical Research Institute as lead sponsor.

NCT NCT01906788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01906788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
THE OPTIMAL TIMING OF PRIMAQUINE TO PREVENT MALARIA TRANSMISSION AFTER ARTEMISININ-COMBINATION THERAPY
Lead sponsor
Kilimanjaro Clinical Research Institute
Phase
Phase 4
Overall status
Unknown status
Start date
May 31, 2013
Completion date
October 31, 2013
Enrollment
250 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria transmission